Indian Journal of Endocrinology and Metabolism

: 2014  |  Volume : 18  |  Issue : 2  |  Page : 166--174

Treat-to-target trials in diabetes

Subhash K Wangnoo1, Bipin Sethi2, Rakesh K Sahay3, Mathew John4, Samit Ghosal5, Surendra K Sharma6 
1 Department of Endocrinology, Indraprastha Apollo Hospital, Delhi, India
2 Department of Endocrinology, Care Hospital, Hyderabad, India
3 Department of Endocrinology, Osmania Medical College and Hospital, Hyderabad, India
4 Department of Endocrinology, Providence Endocrine and Diabetes Specialty Centre, Trivandrum, India
5 Department of Diabetology, Nightingale Hospital, Kolkata, India
6 Department of Endocrinology, Dr. SK Sharma's Diabetes Thyroid and Endocrine Centre, Jaipur, Rajasthan, India

Correspondence Address:
Subhash K Wangnoo
Senior Consultant Endocrinologist, Endocrinology, Indraprastha Apollo Hospital, Delhi Mathura Road, New Delhi - 110 076

Treat-to-target is a therapeutic concept that considers well defined and specific physiologic targets as aims in controlling the pathophysiology of the disease. It has been widely used in diseases that pathophysiology includes, chronic metabolic and physiological disturbances, namely rheumatic conditions, vascular medicine and diabetes. In diabetes, the availability of «DQ»gold-standard«DQ» quantitative measures like fasting plasma glucose and glycated hemoglobin make the application of treat-to-target trials especially pertinent. Treatment modalities which have used single therapeutic agents or combinations or in combination with a variety of titration algorithms and implementation protocols have broadened our understanding of diabetes management with specific reference to insulin initiation and maintenance. Treat-to-target trials have been used to investigate a wide variety of questions including efficacy, safety, effect of treatment on comorbidities and patient satisfaction, ideal mechanisms to implement insulin initiation etc. A more generalized acceptance and implementation of treat-to-target trials may finally revolutionize diabetes management by combining aspects of individual care with standard treatment protocols.

How to cite this article:
Wangnoo SK, Sethi B, Sahay RK, John M, Ghosal S, Sharma SK. Treat-to-target trials in diabetes.Indian J Endocr Metab 2014;18:166-174

How to cite this URL:
Wangnoo SK, Sethi B, Sahay RK, John M, Ghosal S, Sharma SK. Treat-to-target trials in diabetes. Indian J Endocr Metab [serial online] 2014 [cited 2020 Oct 31 ];18:166-174
Available from:;year=2014;volume=18;issue=2;spage=166;epage=174;aulast=Wangnoo;type=0